ReviewBiosensors2023
Post-Assay Chemical Enhancement for Highly Sensitive Lateral Flow Immunoassays: A Critical Review.
Review in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 39 citations in OpenAlex.
- Transport-Reaction-Signal Coupling in Lateral Flow Assays for Next-Generation Point-of-Care Diagnostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Development of a monoclonal antibody-based time-resolved fluorescence immunochromatographic assay strip for rapid and quantitative determination of ubiquitin C-terminal hydrolase L1 in serum.Mikrochimica acta · 2026Article
- An intelligent platform for monitoring human serum albumin in urine based on lateral flow immunochromatography.Mikrochimica acta · 2026Article
- Breaking barriers through driving innovation: sensitivity enhancement strategies for lateral flow assays.Mikrochimica acta · 2025Review
- Heavy Metal Ion Detection Based on Lateral Flow Assay Technology: Principles and Applications.Biosensors · 2025Review
- Black palladium nanoparticle-based lateral flow immunoassay for cardiovascular disease diagnosis.RSC advances · 2025Article
- Point-of-Care Testing for Cardiovascular Disease: A Narrative Review.Current medicinal chemistry · 2025Review
- Lateral Flow Immunosensing ofMicroorganisms · 2024Article
- Ultrasensitive Lateral Flow Immunoassay of Fluoroquinolone Antibiotic Gatifloxacin Using Au@Ag Nanoparticles as a Signal-Enhancing Label.Biosensors · 2024Article
- Highly Sensitive Immunochromatographic Detection of Porcine Myoglobin as Biomarker for Meat Authentication Using Prussian Blue Nanozyme.Foods (Basel, Switzerland) · 2023Article
- High Specific and Rapid Detection of Cannabidiol by Gold Nanoparticle-Based Paper Sensor.Biosensors · 2023Article
- Development of an enhanced sensitivity method for lateral flow immunoassays: An overview of strategies.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Lateral flow immunoassay (LFIA) has found a broad application for testing in point-of-care (POC) settings. LFIA is performed using test strips-fully integrated multimembrane assemblies containing all reagents for assay performance. Migration of liquid sample along the test strip initiates the formation of labeled immunocomplexes, which are detected visually or instrumentally. The tradeoff of LFIA's rapidity and user-friendliness is its relatively low sensitivity (high limit of detection), which restricts its applicability for detecting low-abundant targets. An increase in LFIA's sensitivity has attracted many efforts and is often considered one of the primary directions in developing immunochemical POC assays. Post-assay enhancements based on chemical reactions facilitate high sensitivity. In this critical review, we explain the performance of post-assay chemical enhancements, discuss their advantages, limitations, compared limit of detection (LOD) improvements, and required time for the enhancement procedures. We raise concerns about the performance of enhanced LFIA and discuss the bottlenecks in the existing experiments. Finally, we suggest the experimental workflow for step-by-step development and validation of enhanced LFIA. This review summarizes the state-of-art of LFIA with chemical enhancement, offers ways to overcome existing limitations, and discusses future outlooks for highly sensitive testing in POC conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.